Shares of DENTSPLY International Inc. (XRAY - Free Report) rallied to a new 52-week high of $64.59 on Jun 9 and closed a tad bit lower at $64.43. This represents a strong one-year return of approximately 22.1%, much better than the S&P 500’s return of -0.5% over the same period.
Currently, DENTSPLY has a Zacks Rank #3 (Hold). The stock has a market cap of $14.70 billion and a long-term expected earnings growth rate of 11.1%.
Growth Catalysts
DENTSPLY reported impressive first-quarter 2016 results. Adjusted earnings of 69 cents per share comfortably beat the Zacks Consensus Estimate by 6 cents. Earnings improved almost 17% on a year-over-year basis, primarily driven by strong top-line growth and margin expansion.
DENTSPLY provided a positive guidance. For full-year 2016, the company expects revenue growth of 4% to 6% at constant currency, driven by growth in both of its segments. Adjusted earnings are forecasted in the band of $2.70 to $2.80 per share.
We believe that the combined entity will benefit from revenue and cost synergies in 2016 and beyond. Also, the emerging markets provide significant opportunities for the company as these areas are vastly untapped with low dental products penetration.
However, integration will be a risk in the near term. Additionally, higher capital expenditure on product development coupled with persistent decline in sales is expected to put margins under pressure.
Estimate Revisions
However, the positives outweigh the negatives as evident from the recent estimate revisions. The Zacks Consensus Estimate for fiscal 2016 increased a penny to $2.75 over the last 30 days. Similarly, fiscal 2017 estimate increased by a penny to $3.10 over the same period.
Key Picks
Better-ranked stocks in the broad medical sector include Masimo Corp (MASI - Free Report) , IRadimed (IRMD - Free Report) and Exactech . While Masimo sports a Zacks Rank #1 (Strong Buy), IRadimed and Exactech have a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Shares of DENTSPLY International Inc. (XRAY - Free Report) rallied to a new 52-week high of $64.59 on Jun 9 and closed a tad bit lower at $64.43. This represents a strong one-year return of approximately 22.1%, much better than the S&P 500’s return of -0.5% over the same period.
Currently, DENTSPLY has a Zacks Rank #3 (Hold). The stock has a market cap of $14.70 billion and a long-term expected earnings growth rate of 11.1%.
Growth Catalysts
DENTSPLY reported impressive first-quarter 2016 results. Adjusted earnings of 69 cents per share comfortably beat the Zacks Consensus Estimate by 6 cents. Earnings improved almost 17% on a year-over-year basis, primarily driven by strong top-line growth and margin expansion.
DENTSPLY provided a positive guidance. For full-year 2016, the company expects revenue growth of 4% to 6% at constant currency, driven by growth in both of its segments. Adjusted earnings are forecasted in the band of $2.70 to $2.80 per share.
We believe that the combined entity will benefit from revenue and cost synergies in 2016 and beyond. Also, the emerging markets provide significant opportunities for the company as these areas are vastly untapped with low dental products penetration.
However, integration will be a risk in the near term. Additionally, higher capital expenditure on product development coupled with persistent decline in sales is expected to put margins under pressure.
Estimate Revisions
However, the positives outweigh the negatives as evident from the recent estimate revisions. The Zacks Consensus Estimate for fiscal 2016 increased a penny to $2.75 over the last 30 days. Similarly, fiscal 2017 estimate increased by a penny to $3.10 over the same period.
Key Picks
Better-ranked stocks in the broad medical sector include Masimo Corp (MASI - Free Report) , IRadimed (IRMD - Free Report) and Exactech . While Masimo sports a Zacks Rank #1 (Strong Buy), IRadimed and Exactech have a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on XRAY - FREE
Get the latest research report on MASI - FREE
Get the latest research report on IRMD - FREE